Micro invasive papillary thyroid lesion in a post living donor liver transplant patient: A case report

Khaled Abdel Wahab, Essam Attia, Mohammad Arafa, Mohamed El Sorogy, Mohamed Abdel Wahab

ABSTRACT

Introduction: Liver transplant recipients are at increased risk of developing de novo malignancies. Skin cancers and lymphoma are common in adult transplant recipients, while post-transplant lymphoproliferative disorder (PTLD) is the most common concern in pediatric transplant recipients. De novo malignancy is a well-recognized complication of solid organ transplantation and associated immunosuppression. The development of such malignancies can be caused by a multifactorial combination of individual and regional predispositions to malignancy, pretransplantation disease states, recipient viral status, and the use and intensity of various immunosuppressive regimens to maintain allografts.

Case Report: This report describes a papillary microinvasion of the thyroid in an adult Egyptian male following liver transplantation and declares the need for a high level of suspicion and careful investigation into any abnormal lesion in the long-term follow-up of solid organ transplant patients.

Conclusion: Care should be taken towards any significant symptom or sign suspicious for malignancy for post-transplant patients. The idea of having a routine screening program to detect de novo tumors for those patients should be discussed more.
Micro invasive papillary thyroid lesion in a post living donor liver transplant patient: A case report

Khaled Abdel Wahab, Essam Attia, Mohammad Arafa, Mohamed El Sorogy, Mohamed Abdel Wahab

ABSTRACT

Introduction: Liver transplant recipients are at increased risk of developing de novo malignancies. Skin cancers and lymphoma are common in adult transplant recipients, while post-transplant lymphoproliferative disorder (PTLD) is the most common concern in pediatric transplant recipients. De novo malignancy is a well-recognized complication of solid organ transplantation and associated immunosuppression. The development of such malignancies can be caused by a multifactorial combination of individual and regional predispositions to malignancy, pretransplantation disease states, recipient viral status, and the use and intensity of various immunosuppressive regimens to maintain allografts. Case Report: This report describes a papillary micro invasion of the thyroid in an adult Egyptian male following liver transplantation and declares the need for a high level of suspicion and careful investigation into any abnormal lesion in the long-term follow-up of solid organ transplant patients. Conclusion: Care should be taken towards any significant symptom or sign suspicious for malignancy for post-transplant patients. The idea of having a routine screening program to detect de novo tumors for those patients should be discussed more.

Keywords: De novo malignancy, Immunosuppressive therapy, Liver transplant, Thyroid lesion

INTRODUCTION

Liver transplant recipients are at increased risk of developing de novo malignancies compared to the general population [1–3]. The reported incidence rates range between 3% and 15%, twice that of the general population [4–5].

Skin cancers and lymphoma are common in adult transplant recipients, while post-transplant lymphoproliferative disorder (PTLD) is the most common concern in pediatric transplant recipients [6].

This report describes a papillary micro invasion of the thyroid in an adult male patient following liver transplantation and declares the need for a high level of suspicion and careful investigation into any abnormal lesion in the long-term follow-up of solid organ transplant patients.
CASE REPORT

A 48-year-old Egyptian male had successfully undergone liver transplantation 18 months earlier for hepatocellular carcinoma on top of liver cirrhosis. He had a smooth postoperative period. Then, he used to take cyclosporine and mycophenolate sodium as immunosuppressive therapy.

Eighteen months post-transplant, the patient came with a thyroid nodule that was discovered accidentally after doing a neck ultrasound. There was no prior history of irradiation exposure or any family history of thyroid disease. There was no associated lymphadenopathy, and systemic examination did not reveal any significant findings. He was euthyroid with normal thyroid function.

Neck ultrasound revealed asymmetrically enlarged both thyroid lobes showing foci of calcification and increased perinodular vascularity with the largest nodule was on the left side measuring 1.8x1.2 cm.

Although the initial fine needle aspiration cytology (FNAC) results were inconclusive (colloid nodule with secondary hemorrhage), we decided to perform total thyroidectomy due to the sonographic suspicious criteria. Total thyroidectomy confirmed the diagnosis of micro invasive papillary carcinoma with no capsular and vascular invasion.

Grossly, the lesion appeared as solid firm whitish nodule of about 1.5 cm in diameter. Microscopically, it showed the typical features of papillary carcinoma of the thyroid. There were papillae showing complexity and branching. The papillae were lined by cuboidal cells with stratification. The nuclear features were mostly apparent in the form of ground glass (optically clear), overlapping and grooving (Figures 1 and 2).

The tumor was T1NoMo on TNM staging with no lymph node invasion or distant metastases. Post-operative, suppressive dose of eltroxin was prescribed for the patient with close follow-up.

DISCUSSION

Acquired immunodeficiency conditions are always associated with an increased risk for de novo malignancy. Organ transplantation is considered as an induced state of immunosuppression and, is commonly associated with higher probability for developing neoplasms [7].

De novo malignancy is a well-recognized complication of solid organ transplantation and associated immunosuppression. The risk of developing de novo malignancy after liver transplantation is about 1% per year, but the incidence varies between 3% and 15%, rates that are far greater than those in the general population [1–3].

The development of such malignancies can be caused by a multifactorial combination of individual and regional predispositions to malignancy, pretransplantation disease states, recipient viral status, the use and intensity of various immunosuppressive regimens to maintain allografts [8].

This complication is a major cause of late death in liver transplant recipients, responsible for 25% of the deaths occurring in patients who have survived more than three years post-transplantation [9].

The improvement in immunosuppression and better management of transplanted patients has led to a marked increase in post-LT survival. However, two main pitfalls exist: recurrence of HCV and the long-term side effects of immunosuppression [10].

Protocol for immunosuppressive drugs has changed in the past decades. Overall, the triple therapy for immunosuppression was the standard of care from 1991 to 1995 (cyclosporine, azathioprine and steroids). After 1995, significant changes were developed, consisting primarily in the use of more potent agents [mofetil mycophenolate (MMF), tacrolimus, sirolimus, anti-IL2 receptor antibodies] and the earlier stoppage of second line drugs, such as steroids [7].

Based on the recent introduction of newer and more potent immunosuppressive drugs in the LT arena, Benlloch et al. hypothesized, first, that the number of de novo tumors would increase in recent years; and second, that these tumors may follow a more aggressive behavior [7].

Schmilovitz et al. in their study failed to observe a correlation between tumor development and the type of immunosuppression, the occurrence of rejection episodes, or OKT3 use [11].

Accurate data such as the median interval between solid organ transplantation and the occurrence of the thyroid carcinoma, age range and sex ratio were not discussed in literature.

The patient was commenced on suppressive thyroxine supplements and thyroglobulin levels were monitored to detect recurrent or persistent disease following total thyroidectomy.

CONCLUSION

Care should be taken towards any significant symptom or sign suspicious for malignancy for post-transplant...
patients. The idea of having a routine screening program to detect de novo tumors for those patients should be discussed more.

**********

Author Contributions
Khaled Abdel Wahab – Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Essam Attia – Analysis and interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published
Mohammad Arafa – Analysis and interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published
Mohamed El Sorogy – Analysis and interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published
Mohamed Abdel Wahab – Analysis and interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published

Guarantor
The corresponding author is the guarantor of submission.

Conflict of Interest
Authors declare no conflict of interest.

Copyright
© 2016 Khaled Abdel Wahab et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.

REFERENCES

ABOUT THE AUTHORS


Khaled Mohamed Abdel Wahab is a lecturer of surgical oncology at Mansoura oncology center, Mansoura university in Egypt. He earned the undergraduate degree (M.B.B.CH) from Faculty of medicine, Mansoura university in 2005, Master degree of general surgery in 2010, Master of breast reconstruction from La Sapienza university in Rome, Italy in 2013 and MD degree from Mansoura faculty of medicine in 2015. He has published 13 research papers in national and international academic journals and is an editorial member in four international journals. His research interests include breast surgery and head and neck surgery.
E-mail: khaled14eg@hotmail.com
Essam Attia is working in Surgical Oncology Unit, Mansoura Oncology center, Mansoura University.

Mohammad Arafa is working in Pathology Department, Mansoura University, Egypt.

Mohamed El Sorogy is working in Gastroenterology center, Mansoura university, Egypt.

Mohamed Abdel Wahab is working in Gastroenterology center, Mansoura university, Egypt.
Edorium Journals: An introduction

Edorium Journals Team

About Edorium Journals
Edorium Journals is a publisher of high-quality, open access, international scholarly journals covering subjects in basic sciences and clinical specialties and subspecialties.

Invitation for article submission
We sincerely invite you to submit your valuable research for publication to Edorium Journals.

But why should you publish with Edorium Journals?
In less than 10 words - we give you what no one does.

Vision of being the best
We have the vision of making our journals the best and the most authoritative journals in their respective specialties. We are working towards this goal every day of every week of every month of every year.

Exceptional services
We care for you, your work and your time. Our efficient, personalized and courteous services are a testimony to this.

Editorial Review
All manuscripts submitted to Edorium Journals undergo pre-processing review, first editorial review, peer review, second editorial review and finally third editorial review.

Peer Review
All manuscripts submitted to Edorium Journals undergo anonymous, double-blind, external peer review.

Early View version
Early View version of your manuscript will be published in the journal within 72 hours of final acceptance.

Manuscript status
From submission to publication of your article you will get regular updates (minimum six times) about status of your manuscripts directly in your email.

Our Commitment

Six weeks
You will get first decision on your manuscript within six weeks (42 days) of submission. If we fail to honor this by even one day, we will publish your manuscript free of charge.*

Four weeks
After we receive page proofs, your manuscript will be published in the journal within four weeks (31 days). If we fail to honor this by even one day, we will publish your manuscript free of charge and refund you the full article publication charges you paid for your manuscript.*

Favored Author program
One email is all it takes to become our favored author. You will not only get fee waivers but also get information and insights about scholarly publishing.

Institutional Membership program
Join our Institutional Memberships program and help scholars from your institute make their research accessible to all and save thousands of dollars in fees make their research accessible to all.

Our presence
We have some of the best designed publication formats. Our websites are very user friendly and enable you to do your work very easily with no hassle.

Something more...
We request you to have a look at our website to know more about us and our services.

We welcome you to interact with us, share with us, join us and of course publish with us.

* Terms and condition apply. Please see Edorium Journals website for more information.